title: Laboratory Evaluation of the Efficacy of 10 % Imidacloprid + 2.5 % Moxidectin Topical Solution (Advantage® Multi, Advocate®) for the Treatment of Dirofilaria immitis Circulating Microfilariae in Dogs.
abstract: This study examined the efficacy of 10 % imidacloprid + 2.5 % moxidectin topical solution (Advantage ® Multi, Advocate®, Bayer) for the treatment of circulating microfilariae from dogs naturally infected with Dirofilaria immitis. The study included two groups of 11 dogs each that consisted of two replicates. Replicate 1 contained 12 dogs (6 treated and 6 controls) and replicate 2 contained 10 dogs (5 treated and 5 controls). Six of the 10 dogs in replicate 2 were the controls from replicate 1. All dogs entering the study completed a physical examination including chest radiographs, blood collections for examination of Dirofilaria immitis circulating microfilariae, serum chemistry, complete blood counts and urinalysis. To qualify for the study each dog was required to have a geometric mean ≥ 300 microfilariae per ml of blood from 3 consecutive samples collected during the 8 day acclimation period and a heartworm disease classification of 1 or 2. Dogs were treated on study days 0 and 28. Post-treatment microfilarial counts were performed on study days 1, 2, 3, 7, 14, 21, 28, 29, 35, and 42. Percent microfilarial reduction was determined by comparing the geometric mean number of circulating microfilaria remaining in treated dogs with those remaining in the control dogs post-treatment. Seven days after the first treatment, the geometric mean microfilarial counts in treated dogs were reduced by > 99 % compared to the control dogs. Reduction remained at > 99 % through the end of the study at 42 days after the first treatment (14 days after the second treatment). The results of this study demonstrated that Advantage® Multi for dogs is efficacious for treatment of circulating D. immitis microfilariae in naturally infected heartworm-positive dogs with no treatment-related adverse events observed.
authors.affiliation: Cheri Hill Kennel & Supply, Stanwood, MI, USA, ddb3Bowman@gmail.com.
authors.forename: Dwight D
authors.initials: DD
authors.lastname: Bowman
authors.forename: Samuel D
authors.initials: SD
authors.lastname: Charles
authors.forename: Robert G
authors.initials: RG
authors.lastname: Arther
authors.forename: Terry
authors.initials: T
authors.lastname: Settje
mesh_terms: D000287:Administration, Topical; D000818:Animals; D000871:Anthelmintics / Q000008:administration & dosage / Q000627:therapeutic use; D004183:Dirofilaria immitis / Q000187:drug effects*; D004184:Dirofilariasis / Q000188:drug therapy*; D004283:Dog Diseases / Q000188:drug therapy* / Q000469:parasitology; D004285:Dogs; D004338:Drug Combinations; D005260:Female; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D007306:Insecticides / Q000008:administration & dosage / Q000627:therapeutic use; D018942:Macrolides / Q000008:administration & dosage / Q000627:therapeutic use*; D000073943:Neonicotinoids; D009574:Nitro Compounds / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000871:Anthelmintics; D004338:Drug Combinations; D007093:Imidazoles; D007306:Insecticides; D018942:Macrolides; D000073943:Neonicotinoids; D009574:Nitro Compounds; C082359:imidacloprid; C027837:moxidectin